Fetal hyperinsulinemia increases farnesylation of p21 Ras in fetal tissues.
Even though the role of fetal hyperinsulinemia in the pathogenesis of fetal macrosomia in patients with overt diabetes and gestational diabetes mellitus seems plausible, the molecular mechanisms of action of hyperinsulinemia remain largely enigmatic. Recent indications that hyperinsulinemia "primes" various tissues to the mitogenic influence of growth factors by increasing the pool of prenylated Ras proteins prompted us to investigate the effect of fetal hyperinsulinemia on the activitiy of farnesyltransferase (FTase) and the amounts of farnesylated p21 Ras in fetal tissues in the ovine experimental model. Induction of fetal hyperinsulinemia by direct infusion of insulin into the fetus and by either fetal or maternal infusions of glucose resulted in significant increases in the activity of FTase and the amounts of farnesylated p21 Ras in fetal liver, skeletal muscle, fat, and white blood cells. An additional infusion of somatostatin into hyperglycemic fetuses blocked fetal hyperinsulinemia and completely prevented these increases, specifying insulin as the causative factor. We conclude that the ability of fetal hyperinsulinemia to increase the size of the pool of farnesylated p21 Ras may prime fetal tissues to the action of other growth factors and thereby constitute one mechanism by which fetal hyperinsulinemia could induce macrosomia in diabetic pregnancies.
Stephens
E
E
Veterans Affairs Research Service, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80220, USA.
Thureen
P J
PJ
Goalstone
M L
ML
Anderson
M S
MS
Leitner
J W
JW
Hay
W W
WW
Draznin
B
B
D000273:Adipose Tissue / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D019883:Alkyl and Aryl Transferases / Q000378:metabolism; D000818:Animals; D004195:Disease Models, Animal; D051231:Farnesyltranstransferase; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced / Q000378:metabolism*; D020567:Fetal Weight / Q000187:drug effects; D005333:Fetus; D005947:Glucose / Q000008:administration & dosage; D006946:Hyperinsulinism / Q000139:chemically induced / Q000378:metabolism*; D007262:Infusions, Intravenous; D007328:Insulin; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D008431:Maternal-Fetal Exchange; D018482:Muscle, Skeletal / Q000187:drug effects / Q000196:embryology / Q000378:metabolism; D011247:Pregnancy; D017368:Protein Prenylation / Q000187:drug effects*; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism*; D012756:Sheep; D013004:Somatostatin / Q000008:administration & dosage
D007328:Insulin; D013004:Somatostatin; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D016283:Proto-Oncogene Proteins p21(ras); D005947:Glucose